P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model

Journal of Clinical Investigation

Volumn 115, Issue 11, 2005, Pages 3285-3290

  Cirrito, John R ^a   Deane, Rashid ^b   Fagan, Anne M ^a,c   Spinner, Michael L ^a   Parsadanian, Maia ^a   Finn, Mary Beth ^a   Jiang, Hong ^a   Prior, Julie L ^c   Sagare, Abhay ^b   Bales, Kelly R ^d   Paul, Steven M ^d   Zlokovic, Berislav V ^b   Piwnica Worrns, David ^a,c   Holtzman, David M ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TARIQUIDAR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CAPILLARY ENDOTHELIUM; CONTROLLED STUDY; HIPPOCAMPUS; IN VIVO STUDY; INTERSTITIAL FLUID; KNOCKOUT MOUSE; MICRODIALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN TRANSPORT; SENILE PLAQUE; TRANSGENIC MOUSE; WESTERN BLOTTING;

EID: 27644489474     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI25247     Document Type: Article

References (30)

1. Farris, W., et al. 2003. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 100:4162-4167.
2. Iwata, N., et al. 2004. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J. Neurosci. 24:991-998.
3. Weller, R.O., et al. 1998. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am. J. Pathol. 153:725-733.
4. DeMattos, R.B., Bales, K.R., Cummins, D.J., Paul, S.M., and Holtzman, D.M. 2002. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 295:2264-2267.
5. Shibata, M., et al. 2000. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106:1489-1499.
6. Zlokovic, B.V. 2005. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28:202-208.
7. Deane, R., et al. 2004. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 43:333-344.
8. Zlokovic, B.V., Yamada, S., Holtzman, D., Ghiso, J., and Frangione, B. 2000. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat. Med. 6:718-719.
9. Gottesman, M.M., Fojo, T., and Bates, S.E. 2002. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer. 2:48-58.
10. Ambudkar, S.V., et al. 1999. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:361-398.
11. Schinkel, A.H., et al. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:491-502.
12. Lam, F.C., et al. 2001. beta-Amyloid efflux mediated by P-glycoprotein. J. Neurochem. 76:1121-1128.
13. Vogelgesang, S., et al. 2002. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics. 12:535-541.
14. Hsiao, K., et al. 1996. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:99-102.
15. Mistry, P., et al. 2001. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 61:749-758.
16. Cirrito, J.R., et al. 2003. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 23:8844-8853.
17. DeMattos, R.B., et al. 2004. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 41:193-202.
18. Sharma, V., and Piwnica-Worms, D. 2005. Monitoring multidrug resistance P-glycoprotein drug transport activity with SPECT and PET radiopharmaceuticals. Topics Curr. Chem. 252:155-178.
19. Dyszlewski, M., Blake, H.M., Dahlheimer, J.L., Pica, C.M., and Piwnica-Worms, D. 2002. Characterization of a novel 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity. Mol. Imaging. 1:24-35.
20. Deane, R., et al. 2003. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9:907-913.
21. Deane, R., Wu, Z., and Zlokovic, B.V. 2004. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 35:2628-2631.
22. Hoffmeyer, S., et al. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 97:3473-3478.
23. Marzolini, C., Paus, E., Buclin, T., and Kim, R.B. 2004. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75:13-33.
24. Loeb, M.B., et al. 2004. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease J. Am. Geriatr. Soc. 52:381-387.
25. Piwnica-Worms, D., Rao, V.V., Kronauge, J.F., and Croop, J.M. 1995. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry. 34:12210-12220.
26. Chen, W.S., et al. 2000. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Biochem. Pharmacol. 60:413-426.
27. Luker, G.D., Rao, V.V., Crankshaw, C.L., Dahlheimer, J., and Piwnica-Worms, D. 1997. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. Biochemistry. 36:14218-14227.
28. Holtzman, D.M., et al. 2000. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47:739-747.
29. Bales, K.R., et al. 1997. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17:263-264.
30. Zlokovic, B.V., Mackic, J.B., Wang, L., McComb, J.G., and McDonough, A. 1993. Differential expression of Na,K-ATPase alpha and beta subunit isoforms at the blood-brain barrier and the choroid plexus. J. Biol. Chem. 268:8019-8025.